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Abstract: 
Objectives: To evaluate and compare the performance of six HIV-RNA-based quality of care 
indicators for predicting short-term and long-term outcomes.  
Design: Multinational cohort study.  
Methods: We included EuroSIDA patients on antiretroviral therapy (ART) with ≥3 viral load (VL) 
measurements after baseline (the latest of 01/01/2001 or entry into EuroSIDA). Using multivariate 
Poisson regression  we modelled the association between short-term (resistance, triple-class failure) 
and long-term (all-cause mortality, any AIDS/non-AIDS clinical event) outcomes and the 
indicators: (i) viraemia copy years (VCY), (ii) Consecutive months with VL ≥50copies/mL, (iii) 
percentage of time on ART spent fully suppressed (%FS), (iv) stable on ART, (v) 48 weeks 
snapshot, and (vi) current VL. Indicators were compared using area under the ROC curve (AUC) 
and different measures of model fit. 
Results: Adjusted incidence rate ratios for all outcomes tended to increase with increasing VCY, 
number of consecutive months with VL ≥50copies/mL, current VL and with lower %FS, but the 
gradient of increased risk was weak across strata. None of the indicators reliably identified those at 
risk of long-term outcomes (AUC 0.54-0.58), but performed consistently better with short-term 
outcomes ( triple class failure [AUC 0.67-0.76]) and resistance [AUC 0.64-0.79]). Goodness of fit 
varied with the outcome evaluated, but differences between indicators were small. 
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Conclusions: Differences between quality of care indicators were small and no indicator performed 
consistently better than current VL. Given the simplicity in assessing and interpreting this indicator, 
we propose to use current VL when HIV-RNA-based indicators are used to evaluate the efficacy of 
ART programs. 
 
Keywords/MeSH terms: quality indicators, benchmarking, HIV, viral load, AIDS, outcome 
assessment (health care) 
 
 
Introduction 
Evaluating and comparing the quality of antiretroviral (ART) care is essential to ensure that 
effective ART is provided to individuals with HIV. How best to monitor the quality of care has 
received growing interest in recent years, within [1–4] as well as beyond the HIV field [5–8], and 
using indicators has become a common approach to measuring quality of care, in that they allow for 
some quantification of program performance, allow for comparisons between different programs, 
and may help to identify gaps in care[8]. Clinicians have long sought to find an indicator that 
assesses the quality of ART care in a simple and uniform way, and have proposed several HIV-
RNA-based indicators to distinguish those at high risk of HIV progression from those at low risk. 
Because of the well-known benefits of a suppressed HIV viral load (VL) in reducing mortality and 
morbidity [3,9–11], VL has long been used as an indicator to monitor the efficacy of ART in 
clinical trials as well as in clinical care. Thus, VL suppression at 12 months after ART initiation is a 
WHO-recommended indicator of quality of ART care [3], whereas recent studies suggest that 
cumulative measurements, such as viraemia copy years (VCY) and percentage of follow-up time 
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spent with suppressed VL are also associated with AIDS-related malignancies [12,13], non-AIDS 
defining malignancies [14] and death [15–17].  
 
There is a need to consider whether indicators currently used capture those at highest risk of disease 
progression, and thus which can best be used to evaluate the efficacy of ART programs. While 
some have compared the performance of cross-sectional and cumulative VL-measures at predicting 
various outcomes [12,14,15,17,18], none have evaluated both short-term and long-term outcomes 
comparing a wide range of HIV-RNA-based indicators. An indicator that reliably predicts outcome 
may be used to establish a benchmark level of achievable viral suppression at a population level, 
which allows for comparing ART programs across clinics, countries, and regions [3,7,8]. We 
compared the performance of existing quality of care indicators for a range of short-term (resistance 
and triple class failure) and long-term (all-cause mortality and any AIDS/non-AIDS clinical event) 
outcomes. The aim was to identify the indicator that most reliably can evaluate care in different 
populations.  
 
Patients and methods: 
Patients: EuroSIDA is an observational cohort study of 20,852 HIV-1 positive individuals (as of 
December 2015) followed in 105 clinics in 35 countries across Europe, Israel, and Argentina. 
Details about the study have been published elsewhere [19]. In brief, demographic and clinical data, 
including all CD4-cell counts and HIV-RNA measurements, are collected at enrolment in the study 
and every 6 months thereafter. Data about ongoing ART and reasons for stopping or switching ART 
are collected, as are data on resistance testing, including resistance test results, if available. The date 
of diagnosis of all AIDS-defining illnesses are collected, using the 1993 Centers for Disease 
Control and Prevention definitions, as well as dates of any non-AIDS defining illness. Detailed 
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information about the cause of death is collected using the Coding of Death in HIV (CoDe) system 
[20]. An extensive quality assurance program has been implemented and includes site visits with 
source verification of all major clinical events and monitoring data from a random selection of 
patients followed at each site. 
 
Follow-up: 
We evaluated follow-up time for patients on ART followed in the EuroSIDA study from baseline, 
defined as the latest of January 1
st
 2001 or entry into EuroSIDA, and with ≥3 VL-measurements 
after baseline with detection limit 50copies/mL. The first 4 months after treatment initiation or 
change due to treatment failure and with HIV VL ≥50copies/mL were censored to allow full 
suppression to occur [21]. VL-measurements were censored if the lower limit of detection was >50 
copies/mL. To model VL between measurements, each measured value was carried forward until 
the next measurement or for a maximum of 12 months, after which it was censored and restarted at 
the next VL-measurement. Follow-up was until death or last follow-up, and multiple events were 
allowed (not for triple class failure or all-cause mortality). ART was defined as receiving any ≥3 
antiretrovirals from any class. Virological suppression was defined as VL <50copies/mL. Triple 
class failure of the three original ART classes was defined as virological failure (at least 4 months 
continuous use of a drug with VL >500copies/mL) of  two nucleoside reverse transcriptase 
inhibitors (NRTI), one non-nucleoside reverse transcriptase inhibitor (NNRTI) and one protease 
inhibitor(PI)[22,23]. Resistance was defined as any NRTI, NNRTI, or major PI mutation. 
 
Calculating the six quality of care indicators: 
The six quality of care indicators were calculated as illustrated in figure 1. Current VL was the 
value of the most recent HIV-RNA within 12 months of assessment. Viraemia copy years (VCY) 
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[17] was calculated as the area under the curve using the trapezoidal rule. Values below the assay 
detection limit were set to zero, meaning that an individual would not accumulate VCY if fully 
virologically suppressed. Consecutive months with VL ≥50copies/mL was calculated as a summation 
of the number of consecutive months with VL ≥50copies/mL. Percentage of time on ART spent 
fully suppressed (%FS) [13,14,24,25] was calculated as the cumulative percentage of time on ART 
spent with VL <50copies/mL, and was modeled as a categorical value (0-69%, 70-79%, 80-89%, 
90-94%, 95-99%, 100%). The 48 weeks snapshot [3] assesses the virological outcome at 48 weeks 
(window ±24 weeks) after treatment initiation or change. VL <50copies/mL was characterized as 
“suppressed”, VL ≥50copies/mL or missing was characterized as “not suppressed”. Stable on ART 
was defined as being on the same ART regimen for a minimum of the prior 12 months with at least 
1 VL <50copies/mL during that time. Those with missing VL were considered “not stable on 
ART”. 
 
Incidence rates: 
All events occurring during the follow-up time were recorded and Poisson regression, using 
generalized estimating equations, was used to model incidence rates (IR) of each endpoint, 
adjusting for age* (per 10 years older), gender, body mass index, smoking status*, mode of 
transmission, ethnicity, region of residence, CD4 cell count*, cumulative years on ART*, current PI 
use*, current NNRTI use*, cumulative number of antiretrovirals used historically*, prior AIDS 
events*, prior non-AIDS events* (cardiovascular disease, end stage liver disease, end stage renal 
disease, pancreatitis), prior AIDS/non-AIDS-defining malignancies*, prior hepatitis B*, prior 
hepatitis C*, diabetes*, and hypertension*. Resistance models were also adjusted for prior 
resistance*. Time updated variables are indicated by *. Due to low numbers, incidence rates could 
not be calculated for triple class failure at different levels of current VL.  
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Comparison of quality of care indicators: 
We compared the performance of each quality indicator model with a reference model containing 
current VL by calculating discrimination and goodness of fit. Logistic regression models were used 
to assess the Area Under the Receiver Operating Curve (AUC) for each model’s ability to identify 
those at risk of developing each endpoint within a common, fixed follow-up time of 5 years after 
baseline. Because the 48 weeks snapshot is a time-fixed indicator at 48 weeks, comparisons with 
this model were performed prospectively up to 5 years after this 48 week mark. We compared the 
goodness of fit of models containing each indicator only, to models containing any combination of 
indicator information, and compared global model fit using generalized score tests [27] and QIC 
statistics (Quasi-likelihood under the Independence model Criterion)[28].  
 
Results:  
Of 18,786 patients in the EuroSIDA study at the time of analysis, 11,860 had ≥3 VL measurements 
available after baseline. The majority of patients were Caucasian (86.8%), male (75.0%) and with 
median age 41 years (interquartile range [IQR] 35-48). The predominant route of infection was men 
who have sex with men (44%) followed by heterosexual transmission (31%) and injecting drug use 
(18%). Median baseline CD4 was 430 cells/mm
3 
(IQR 283-609), median baseline HIV-RNA was 
<50copies/mL (IQR 39-79). Patients contributed with a median of 4.9 (IQR 2.3–8.4) person years 
of follow-up (PYFU) and 14 (IQR 5-24) VL-measurements with a median time between two 
consecutive measurements of 10 months (IQR 7.5-12.75). The majority of patients (95%) had at 
least 1 HIV-RNA <50copies/mL during follow-up, and patients had been on ART for a median of 
4.5 (IQR 3.2-5.9) years.  
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During 64,658 PYFU 561 patients died with non-AIDS related conditions being the main causes of 
death (n=487, 86.6%). The median time between last VL-measurement and any AIDS/non-AIDS 
clinical event was 3.0 months (IQR 1.0 -5.0) and until death 3.0 (IQR 2.0-5.9) months. 
Proportionally more follow-up time was censored in East and Central Eastern Europe compared 
with other regions (41% versus 28% of total follow-up time censored). The numbers of other events 
were as follows: triple class failure n=78, resistance n=779, non-fatal AIDS/non-AIDS defining 
event n=1620 of which 57% were not AIDS-related.  
 
Incidence rates:  
Table 1 shows the crude incidence rates per 1000 PYFU of triple class failure, resistance, any 
AIDS/non-AIDS clinical event and all-cause mortality, separately by each quality of care indicator. 
The number of events, person years of follow-up and incidence rates for strata of each indicator are 
shown. There were 1,726 AIDS/non-AIDS clinical events among patients with current VL <50 
copies/mL during 55,049 PYFU, giving a crude incidence rate of 31.4 (95% Confidence Interval 
[CI] 29.9, 32.9) per 1000 PYFU, rising to IR 99.7 (95%CI 85.4, 116.5) per 1000 PYFU at current 
VL >10,000 copies/mL. Overall, incidence rates of any outcome increased across strata of 
increasing current VL, increasing VCY, with a higher number of consecutive months with VL 
≥50copies/mL, and with decreasing %FS. 
Figure 2 shows adjusted incidence rate ratios (aIRR) for each of the four outcomes by quality of 
care indicator. The figures are ordered horizontally by indicator and vertically by outcome. The 
adjusted incidence rate ratios increased across strata of increasing current VL, increasing VCY, 
with higher number of consecutive months with VL ≥50copies/mL and with lower %FS. However, 
the gradient varied greatly depending on the outcome evaluated. For example, compared to those 
with current VL<50 copies/mL, the rate of any AIDS/non-AIDS clinical event was similar (aIRR 
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0.9 [95%CI 0.8, 1.1, p=0.452]) for those with current VL 51-500 copies/mL, increasing to aIRR 1.6 
(1.1, 2.3, p=0.007) at 501-1,000 copies/mL, aIRR 0.98 (0.8, 1.3, p=0.900) at 1,001-10,000 
copies/mL, and aIRR 1.9 (1.6, 2.3, p<0.0001) for those with current VL >10,000 copies/mL. Thus, 
although the incidence of any AIDS/non-AIDS clinical event was significantly higher at high 
(>10,000 copies/mL) compared with low current VL (≤50 copies/mL), the gradient was weak 
across strata of increasing current VL. Furthermore, those with current VL >10,000 copies/mL had 
a 32.6 times higher (aIRR 32.6 [95%CI 23.6, 45.1, p<0.0001]) incidence of resistance than those 
with current VL <50 copies/mL, whereas the adjusted incidence rate ratios for all-cause mortality 
(aIRR 1.6 [1.1, 2.2, p=0.011]) and for any clinical event (aIRR 1.9 [1.6, 2.3, p<0.0001]) were 
considerably lower when comparing the same two strata of current VL. All indicators were weakly 
associated with all-cause mortality and any AIDS/non-AIDS clinical event, but were significantly 
associated with triple class failure and resistance.   
Patients who were not stable on ART had a higher incidence rate of all outcomes than those who 
were (any clinical event aIRR 1.2 [1.1, 1.4, p=0.003], all-cause mortality aIRR 1.1 [0.9, 1.3, 
p=0.536], resistance aIRR 12.4 [9.4, 16.3, p<0.0001], triple class failure aIRR 7.30 [IQR 4.3, 12.5, 
p<0.0001] for not stable on ART compared with stable on ART). 
Comparison of quality of care indicators: 
As shown in figure 3, the moderate association between any indicator and clinical events was 
reflected in a poor discriminative ability with AUC-scores between 0.54-0.58 for identifying those 
at risk of any clinical event or all-cause mortality. For a model containing current VL, AUC was 
0.57 (95%CI 0.55,0.59) for predicting any AIDS/non-AIDS clinical event and 0.56 (95%CI 
0.53,0.60) for predicting all-cause mortality. The differences in AUC between indicators were 0.03 
or less. Two models were significantly different from the reference current VL-model, but neither 
performed better than current VL at identifying those at risk of any clinical event. Adding VCY to a 
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model containing current VL contributed with some information at predicting any AIDS/non-AIDS 
clinical event (AUC 0.58 [95%CI 0.56,0.60]), but did not increase the AUC compared with current 
VL alone (AUC 0.58 [0.55,0.60], p for comparison =0.02). The indicators were consistently better 
at identifying those at risk of short-term outcomes (AUC 0.74-0.86 for predicting triple class 
failure, AUC 0.74-0.82 for predicting resistance). Adding %FS to a model containing current VL 
increased AUC for predicting resistance from 0.79 (0.75,0.82) to 0.82 (0.79,0.85, p=0.001). The 
predictive value of all other indicators was equal to or significantly worse than current VL at 
identifying short-term outcomes. Sensitivity analyses using an assay cut-off <500 copies/mL 
showed similar results. 
 
Table 2 shows the results of the generalized score tests. Each row shows the χ²-values and 
corresponding p-values for a model containing all indicators, and for separate models leaving out 
each of the indicators one at a time. A higher χ², and corresponding lower p-value, indicates that 
model fit decreases when the indicator is left out. In other words, an indicator that improves model 
fit will have a higher χ² and a lower p-value. Thus, leaving out consecutive months with VL ≥50 
copies/mL did not change model fit significantly (χ² = 9.36, p=0.096), whereas leaving out current 
VL did (χ² = 30.38, p<0.0001) when modelling the association between indicators and any 
AIDS/non-AIDS clinical event. Likewise, there was no evidence that leaving out VCY from the 
model significantly changed model fit (χ² = 16.22, p=0.006), whereas current VL seemed to add 
information to a model of any AIDS/non-AIDS clinical event (χ² = 29.68, p<0.0001). Again, the 
best fitting models depended on the outcome evaluated: including VCY gave the best model fit for 
triple class failure, current VL for resistance and any clinical event, and including %FS gave the 
best fit for all-cause mortality. Although cumulative measures contributed with some information, 
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goodness of fit was not substantially improved when compared to the model containing current VL 
only.  
Using QIC to identify the best fitting models, we again found that the models were ranked 
differently depending on the outcome evaluated (data not shown).  
 
Discussion: 
We compared six indicators of quality of ART care in the EuroSIDA study. We found that the 
predictive value of each indicator depended on the outcome evaluated, and no indicator was 
consistently better than the others. Whereas current VL most reliably identified those at risk of 
developing short-term outcomes such as resistance and triple class failure, cumulative indicators 
were more informative for long-term outcomes such as the risk of any AIDS/non-AIDS clinical 
event and all-cause mortality. All indicators generally performed better at predicting short-term 
outcomes than clinical events. Using a range of statistical methods, we repeatedly found that, 
although cumulative measures had some prognostic value, only little extra prognostic information 
could be gained compared to current VL alone. From a clinical viewpoint, using current VL has 
some obvious advantages, as it is simpler to both understand and calculate than cumulative 
indicators. Further, a strength of using current VL as a quality of care indicator is that it reflects 
current care, rather than reflecting previous clinical practices, as do some cumulative HIV-RNA-
based indicators. 
 
Our findings are unlike some recent studies that found an association between cumulative HIV 
measures and varying clinical outcomes [12–17]. An association between higher viraemia copy 
years and mortality was reported by some [15], while others found an association only if VCY was 
dichotomized to high compared with low values [16,18]. We, too, found that high VCY was 
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associated with a higher risk of any of the evaluated outcomes compared with VCY=0, but the 
gradient was weak across strata of VCY. Further, this pattern was similar for any indicator with 
evidence of a difference in clinical outcome between high and low values of the indicator, but a 
weak gradient across strata. However, the gradient of increased risk was consistently higher for 
short-term outcomes. VCY was originally derived in a cohort of HIV-positive men who did not 
receive effective ART [17], and it is quite possible that VCY is a reliable indicator in such high-risk 
patients, but may not perform as well in a population on ART with an abundance of low-risk 
patients.  
 
Few other studies have investigated the association between quality of care indicators and short-
term outcomes. Some have investigated the association with cross-sectional VL measures and 
development of resistance [29,30] and triple class failure [31], whereas studies of the association 
with cumulative VL are few. One previous EuroSIDA study found that low VCY was associated 
with a high rate of resistance development, and hypothesized that a high VCY is a surrogate for low 
resistance pressure due to poor adherence [32]. Others found some evidence of association between 
a higher cumulative time on ART with VL >500copies/mL and development of triple class failure 
following virological failure of an NNRTI [22].  
 
Monitoring and improving HIV care has received much interest in recent years and researchers have 
attempted to develop new or synthesize existing indicators into a model for assessing care [1,2,4]. A 
clinical event may be thought of as the result of the comprehensive care provided to a patient.  For 
HIV-positive individuals, however, there is a substantial time-delay between starting ART and 
developing clinical events, and HIV-RNA serves as a surrogate for health outcomes that could 
otherwise only be measured after years. As indicated by some, there are limitations to using viral 
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suppression as a general measure of quality of care, as a range of patient-specific factors may affect 
the level of suppression [33]. Although the absence of viral suppression is thus not always a marker 
of poor quality of care, we believe it may help to identify high and poor performing providers, and 
may serve as a useful benchmark to allow comparisons between programs nationally and 
internationally.  
However, good quality HIV care is multifaceted, and our findings underline that understanding and 
measuring the quality of ART programs goes beyond measuring HIV-RNA. Comparing current 
levels of viral suppression between countries may thus be the first step to subsequently assess the 
reasons for the observed differences, and future research should seek to further uncover the linkage 
between differences in suppression rates and differences in HIV management. Current VL should 
thus be one indicator in a comprehensive set of core indicators to benchmark HIV care across 
Europe. 
 
Our study has several strengths. We were able to externally validate and compare a range of 
different indicators using a variety of outcomes, including key clinical outcomes, in the same large 
cohort with a high number of person years. Further, our study has the advantage of comparatively 
longer follow-up times, allowing for a more accurate assessment of the indicators’ prognostic value 
for long-term outcomes. Few other studies have compared the association between cross-sectional 
and cumulative measures and incidence of clinical outcomes, and none have evaluated both long-
term and short-term outcomes using the same dataset.  
 
Our study also has certain limitations. A shortcoming of HIV-RNA-based quality indicators is that 
they are inherently insensitive to those with missing VL-measurements, but capture only those that 
are to some extent retained in care. We chose a conservative approach by treating all missing values 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
  
as failure, giving a correspondingly conservative estimate of care. However, viral loads may be 
missing for those on ART but not in care, those refusing VL monitoring, patients with poor 
adherence and with poor clinic attendance, or those lost to follow-up. Or they may be missing for 
patients with poor or no access to VL monitoring or may be caused by reporting delays. The 
implications for these patients may vary greatly, and understanding the relative contributions of the 
different scenarios is important to determine where effective interventions should be focused.  
 
To avoid censoring a large number of people with ≥6 months between two consecutive VL-
measurements, we defined stable on ART as being on the same ART-regimen for a minimum of the 
prior 12 months with at least one fully suppressed VL during that time, rather than two (confirmed 
failure). Virological “blips” are not uncommon [34], and therefore the number of individuals that 
were not stable on ART may have been overestimated, leading to an underestimation of the 
performance of this indicator. Finally, as not all sites have access to assays with a sensitivity of 
50copies/mL, proportionally more follow-up time was censured in Eastern Europe compared with 
other regions, which may also bias our results, although our sensitivity analyses using 500 
copies/ml as a lower limit of detection showed similar results. 
 
Conclusion: 
We compared six indicators of quality of ART care with the goal of identifying the indicator that 
most reliably can evaluate and compare the performance of ART programs. Using a range of 
statistical methods, we found that differences between the indicators were small, and no indicator 
performed consistently better than current VL. Due to the simplicity in assessing and interpreting 
this indicator, we propose to use current VL when HIV-RNA-based indicators are used to evaluate 
the efficacy of ART programs, and we propose that quantifying the level of current VL in a 
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population on ART allows for comparing and benchmarking the quality of HIV care across 
populations. 
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Any AIDS/non-AIDS clinical event All-cause mortality Resistance Triple class failure 
Indicator Events PYFU IR/1,000PYFU Events PYFU IR/1,000PYFU Events PYFU IR/1,000PYFU Events PYFU IR/1,000PYFU 
Current viral load (copies/mL) 
0-49 1726 55049 31.4 ( 29.9, 32.9) 456 55049 8.3 ( 7.6, 9.1) 74 8445 8.8 ( 7.0, 11.0) 32 52910 0.6 ( 0.4, 0.9) 
50-500 163 5084 32.1 ( 27.5, 37.4) 37 5083 7.3 ( 5.3, 10.1) 100 1195 83.7 ( 68.8, 101.8) 28 4686 6.0 ( 4.1, 8.7) 
501-1,000 46 797 57.7 ( 43.3, 77.1) 9 797 11.3 ( 5.9, 21.7) 68 261 260.8 ( 205.6, 330.8) 0 695 0.0 ( 0.0, 0.0) 
1,001-10,000 70 1860 37.6 ( 29.8, 47.6) 19 1860 10.2 ( 6.5, 16.0) 287 737 389.5 ( 347.0, 437.3) 0 1554 0.0 ( 0.0, 0.0) 
>10,000 159 1595 99.7 ( 85.4, 116.5) 38 1595 23.8 ( 17.3, 32.8) 246 678 362.7 ( 320.1, 411.0) 7 1220 5.7 ( 2.7, 12.0) 
missing 17 276 61.7 (38.4, 99.25) 2 276 7.3 (1.8, 29.0) 4 33 123.0 (46.2, 327.8) 11 264 41.7 (23.1, 75.3) 
Viraemia copy years (copies x years/mL) 
0 745 27787 26.8 ( 25.0, 28.8) 176 27787 6.3 ( 5.5, 7.3) 43 2270 18.9 ( 14.1, 25.5) 2 27317 0.1 ( 0.0, 0.3) 
1-58 406 13508 30.1 ( 27.3, 33.1) 105 13508 7.8 ( 6.4, 9.4) 29 1647 17.6 ( 12.2, 25.3) 2 13186 0.2 ( 0.0, 0.6) 
59-140 115 3931 29.3 ( 24.4, 35.1) 31 3931 7.9 ( 5.6, 11.2) 28 659 42.5 ( 29.4, 61.6) 3 3815 0.8 ( 0.3, 2.4) 
141-271 99 2290 43.2 ( 35.5, 52.7) 25 2290 10.9 ( 7.4, 16.2) 34 415 81.9 ( 58.5, 114.7) 3 2195 1.4 ( 0.4, 4.2) 
272-1127 148 4407 33.6 ( 28.6, 39.5) 40 4407 9.1 ( 6.7, 12.4) 118 1269 93.0 ( 77.7, 111.4) 6 4075 1.5 ( 0.7, 3.3) 
>1127 668 12737 52.5 ( 48.6, 56.6) 184 12737 14.5 ( 12.5, 16.7) 527 5088 103.6 ( 95.1, 112.8) 62 10740 5.8 ( 4.5, 7.4) 
Consecutive months with VL ≥50 copies/mL (months) 
0 1734 55280 31.4 ( 29.9, 32.9) 456 55280 8.3 ( 7.5, 9.0) 74 8440 8.8 ( 6.9, 11.0) 33 53147 0.6 ( 0.4, 0.8) 
1-2 69 2208 31.3 ( 24.7, 39.6) 12 2208 5.4 ( 3.1, 9.6) 97 531 182.7 ( 149.7, 222.9) 2 2027 1.0 ( 0.3, 3.9) 
3-4 55 1586 34.7 ( 26.6, 45.2) 8 1586 5.0 ( 2.5, 10.1) 79 395 200.2 ( 160.6, 249.6) 7 1441 4.9 ( 2.3, 10.2) 
5-7 70 1421 49.3 ( 39.0, 62.3) 16 1421 11.3 ( 6.9, 18.4) 104 385 270.2 ( 222.9, 327.4) 4 1268 3.2 ( 1.2, 8.4) 
8-17 126 2162 58.3 ( 49.0, 69.4) 30 2162 13.9 ( 9.7, 19.9) 224 723 309.8 ( 271.8, 353.1) 19 1844 10.3 ( 6.6, 16.2) 
>18 127 2000 63.5 ( 53.4, 75.6) 39 2000 19.5 ( 14.3, 26.7) 201 875 229.7 ( 200.0, 263.8) 13 1601 8.1 ( 4.7, 14.0) 
Percentage of time on ART spent fully suppressed (%) 
0-59 591 12268 48.2 ( 44.4, 52.2) 141 12268 11.5 ( 9.7, 13.6) 666 4335 153.7 ( 142.4, 165.8) 53 10363 5.1 ( 3.9, 6.7) 
60-69 119 3269 36.4 ( 30.4, 43.6) 30 3269 9.2 ( 6.4, 13.1) 28 842 33.3 ( 23.0, 48.2) 5 3035 1.7 ( 0.7, 4.0) 
70-79 171 4551 37.6 ( 32.4, 43.7) 48 4551 10.6 ( 8.0, 14.0) 29 1076 27.0 ( 18.7, 38.8) 6 4318 1.4 ( 0.6, 3.1) 
80-89 265 7725 34.3 ( 30.4, 38.7) 76 7725 9.8 ( 7.9, 12.3) 26 1403 18.5 ( 12.6, 27.2) 9 7464 1.2 ( 0.6, 2.3) 
90-94 206 5796 35.5 ( 31.0, 40.7) 67 5796 11.6 ( 9.1, 14.7) 9 856 10.5 ( 5.5, 20.2) 1 5634 0.2 ( 0.0, 1.3) 
95-99 146 5203 28.1 ( 23.9, 33.0) 37 5203 7.1 ( 5.2, 9.8) 2 813 2.5 ( 0.6, 9.8) 2 5077 0.4 ( 0.1, 1.6) 
100 683 25846 26.4 ( 24.5, 28.5) 162 25846 6.3 ( 5.4, 7.3) 19 2024 9.4 ( 6.0, 14.7) 2 25437 0.1 ( 0.0, 0.3) 
Stable on ART 
No 586 12582 46.6 ( 43.0, 50.5) 140 12582 11.1 ( 9.4, 13.1) 708 3740 189.3 ( 175.9, 203.8) 52 11171 4.7 ( 3.6, 6.1) 
Yes 1595 52077 30.6 ( 29.2, 32.2) 421 52077 8.1 ( 7.4, 8.9) 71 7609 9.3 ( 7.4, 11.8) 26 50158 0.5 ( 0.4, 0.8) 
Total 
2181 64658 33.7 ( 32.3, 35.2) 561 64658 8.7 ( 8.0, 9.4) 779 11348 68.7 ( 64.0, 73.6) 78 61329 1.3 ( 1.0, 1.6) 
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Table 1: Crude incidence rates (IR) per 1000 person years of follow-up (PYFU) of four outcomes by quality of care indicator 
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Any AIDS/non-AIDS clinical 
event 
All-cause mortality Resistance Triple class failure 
Effect of 
dropping 
indicator 
Effect of 
dropping 
current VL 
Effect of 
dropping 
indicator 
Effect of 
dropping 
current VL 
Effect of 
dropping 
indicator 
Effect of 
dropping 
current VL 
Effect of 
dropping 
indicator 
Effect of 
dropping 
current VL 
Indicator χ² 
p-
value 
χ² 
p-
value 
χ² 
p-
value 
χ² 
p-
value 
χ² 
p-
value 
χ² 
p-
value 
χ² 
p-
value 
χ² 
p-
value 
Viraemia copy years  16.22 0.006 29.68 <0.0001 11.57 0.041 9.03 0.108 24.52 0.0002 156.43 <0.0001 49.26 <0.0001 17.45 0.0016 
Consecutive months with 
VL ≥50 copies/mL 
9.36 0.096 30.38 <0.0001 13.66 0.018 5.78 0.328 13.69 0.018 310.55 <0.0001 20.79 0.0009 10.64 0.011 
Percentage of time on ART 
spent fully suppressed 
12.95 0.024 33.74 <0.0001 14.65 0.012 9.85 0.08 43.80 <0.0001 315.55 <0.0001 35.81 <0.0001 17.81 0.0001 
48 weeks snapshot* 5.41 0.020 26.1 <0.0001 3.52 0.061 8.33 0.140 0.38 0.540 209.08 <0.0001 - - - - 
Stable on ART 1.27 0.260 30.59 <0.0001 0.06 0.813 8.42 0.135 16.24 <0.0001 358.76 <0.0001 8.86 <0.0001 15.77 0.0004 
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Table 2: Contribution of quality of care indicators to prediction of outcomes. The figure gives the values of the generalized score tests for each indicator by 
outcome, showing the effect on model fit when leaving out each quality of care indicator separately from the model. A higher χ², and corresponding lower p-
value, indicates that model fit decreases when the indicator is left out of the model. *48 weeks snapshot compared from 48 weeks after treatment initiation 
or change. Analyses not done for the association between triple class failure and 48 weeks snapshot because of too few events.  
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
